Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder

Abstract

In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.